We have located links that may give you full text access.
Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization.
PURPOSE: To compare two different initial dosing regimens of intravitreal ranibizumab used to treat myopic choroidal neovascularization.
METHODS: A total of 61 eyes of 56 patients were treated: 26 eyes received a single injection followed by treatment pro re nata (1+ PRN), while 35 eyes first received 3 consecutive monthly injections (3+ PRN).
RESULTS: The mean follow-up was 53 ± 16 months. The visual acuities were 51.9 ± 16.2 letters with 3+ PRN and 53 ± 22.4 letters with 1+ PRN at baseline (p = 0.824); 69.5 ± 12.3 and 69 ± 15.1 letters, respectively, at 12 months; and 67.1 ± 16.2 and 66.4 ± 19.7 letters, respectively, at the end of follow-up (p = 0.877). Mean survival until first retreatment after the loading dose was 36.9 ± 6.1 months with 3+ PRN and 19.2 ± 5.4 months with 1+ PRN (p < 0.001).
CONCLUSIONS: Both dosing regimens led to similar visual outcomes. For eyes given a single injection in the first quarter, retreatment was needed appreciably earlier.
METHODS: A total of 61 eyes of 56 patients were treated: 26 eyes received a single injection followed by treatment pro re nata (1+ PRN), while 35 eyes first received 3 consecutive monthly injections (3+ PRN).
RESULTS: The mean follow-up was 53 ± 16 months. The visual acuities were 51.9 ± 16.2 letters with 3+ PRN and 53 ± 22.4 letters with 1+ PRN at baseline (p = 0.824); 69.5 ± 12.3 and 69 ± 15.1 letters, respectively, at 12 months; and 67.1 ± 16.2 and 66.4 ± 19.7 letters, respectively, at the end of follow-up (p = 0.877). Mean survival until first retreatment after the loading dose was 36.9 ± 6.1 months with 3+ PRN and 19.2 ± 5.4 months with 1+ PRN (p < 0.001).
CONCLUSIONS: Both dosing regimens led to similar visual outcomes. For eyes given a single injection in the first quarter, retreatment was needed appreciably earlier.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app